Skip to main content
Quest Diagnostics

Analytical Validation of the Haystack MRD Assay for the Detection of Extremely Low ctDNA in Solid Tumor Patients

AMP 2024

Association for Molecular Pathology 2024 Annual Meeting & Expo

Vancouver, Canada, Nov 19-23, 2024

Poster presentation: Analytical Validation of the Haystack MRD Assay for the detection of extremely low ctDNA in Solid Tumor Patients

Authors: Prathapam R, Champion K, Blakely K, Powers S, Graham J, Tigh A, Goos-Root D, Sass C, Angeloni T, Acab A, Gutierrez R, Harding J, Liu Y, Cleveland C, Clark M, Downton M, Helfrich-Kroger A, Querfurth R, Brown E, Maramica I, Glodosky C, Haskell B, Kaplan J, Ryder M, Bramlett K

Specialty: Oncology

Related content

Test FAQ
Haystack MRD Testing
Publication
NGS defined measurable residual disease MRD after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
On-Demand Webinar
Prognostic Melanoma Molecular Testing to Inform Better Patient Care

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.